Doxorubicin-Induced Cardiomyopathy Latest Advances
Find the Latest Research About Doxorubicin-Induced Cardiomyopathy
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1582 publications
CHK1 activates mitophagy to attenuate cardiac aging via inhibiting AHSA1-ubiquitination.
Journal: Redox biology
Published: April 30, 2026
Multiomics Analysis Reveals the Protective Effect of a Novel Bioactive Peptide (BP1) in Cardiomyopathy Using a Zebrafish Model.
Journal: Journal of proteome research
Published: April 14, 2026
EV-Mediated Intracardiac Crosstalk Mitigates Doxorubicin-Induced Cardiotoxicity.
Journal: Circulation research
Published: April 08, 2026
Midkine, a heparin-binding growth factor, exacerbates heart failure in dilated cardiomyopathy via NRXN1 regulation and inflammatory responses.
Journal: The international journal of biochemistry & cell biology
Published: March 09, 2026
Targeted nano delivery of p53 DNA and carvedilol for the treatment of dilated cardiomyopathy in a rat model.
Journal: Nanomedicine (London, England)
Published: February 25, 2026
Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies.
Journal: Drug metabolism reviews
Published: February 10, 2026
Discovery and Structure-Activity Relationship Studies of Diazepine Derivatives as a New Class of Ferroptosis Inhibitors with Potent Efficacy in the Doxorubicin-Induced Cardiomyopathy Model.
Journal: Journal of medicinal chemistry
Published: January 30, 2026
Gain-of-Function Variant TRPC6 A404V Is Associated With Doxorubicin-Related Cardiomyopathy.
Journal: Circulation. Genomic and precision medicine
Published: January 28, 2026
Targeting SIRT1 stability: arctiin ameliorates doxorubicin-induced cardiac injury by inhibiting SMURF2 binding and enhancing protective lipid metabolism.
Journal: Frontiers in pharmacology
Published: January 28, 2026
An Inulin-Based Fiber-Rich Diet Alleviates Doxorubicin Cardiotoxicity via the fMet-KCNE2 Axis to Attenuate Ferroptosis and Oxidative Stress.
Journal: Free radical biology & medicine
Published: January 21, 2026
Biomimetic astragaloside-IV-loaded mesoporous silica nanoparticles for treatment of dilated cardiomyopathy.
Journal: Frontiers in pharmacology
Published: January 18, 2026
Ferroptosis inhibition via Nrf2/GPX4 activation underlies the broad-spectrum cardioprotection by human α1-antitrypsin.
Journal: International journal of biological macromolecules
Published: January 17, 2026
Last Updated: 06/30/2026